Scintigra is developing diagnostic positron emission tomography (PET) and Single Photon Emission Computerized Tomography (SPECT) radiopharmaceuticals that are capable of enhancing the medical management of oncology, Alzheimer's Disease, Parkinson's Disease, and heart disease patients.  Based on the work of Dr. Mark Goodman at Emory University, the company has developed proprietary compounds and has demonstrated their potential to detect the earliest stages of disease in preclinical studies.